3 Things That Matter Most for Eli Lilly Now

Eli Lilly (NYSE: LLY) has experienced remarkable success in the GLP-1 weight-loss space, with Mounjaro sales rising 91% and Zepbound sales increasing by 46% in the second quarter of 2026. The newly introduced GLP-1 pill, Foundayo, also began generating revenue. These weight-loss drugs contributed nearly $15 billion to the company's $23 billion in revenue for the quarter, accounting for nearly two-thirds of its top line.

Investors should consider these three factors when evaluating Eli Lilly's current position: the impressive growth of their weight-loss products, the company's heavy reliance on these drugs for revenue, and the potential challenges that come with such a dominant position in the market.

Brief written by urgent.news from Motley Fool's own syndicated text. Machine-written — may contain errors; check the original before relying on it.